Stromedix (Cambridge, MA) development-stage biotechnology company focused on therapies for fibrosis, closed a $25M Series B financing. Participants include New Leaf Venture Partners, Bessemer Venture Partners, Red Abbey Venture Partners, Atlas Venture and Frazier Healthcare Ventures.